Brepocitinib, a selective TYK2/JAK1 inhibitor, mitigates neutrophilic inflammation and glucocorticoid receptor-β expression in COPD

American Journal of Physiology-Lung Cellular and Molecular Physiology 2026 Open access

Read full text
Authors: Barsha Baisakhi Nayak, Thomas Bärnthaler, Rishi Rajesh, Julia Teppan, Theresa Gogg, Philipp Douschan, Nikolaus Kneidinger, Anne M. van der Does, Pieter Sicco Hiemstra, Ákos Heinemann, Eva Böhm
DOI: 10.1152/ajplung.00237.2025
Cited by: 1
References: 104

Abstract

This study reveals that the IL-23/IL-17A axis drives neutrophil activation and GRβ upregulation in COPD through TYK2/JAK1-mediated signaling. Inhibition of TYK2/JAK1 with brepocitinib reduced neutrophilic inflammation and restored the GRα/GRβ balance in neutrophils, identifying TYK2/JAK1 as promising therapeutic targets for severe COPD.

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Asthma and respiratory diseases Psoriasis: Treatment and Pathogenesis

Publication details

Journal / source
American Journal of Physiology-Lung Cellular and Molecular Physiology
Publisher
American Physiological Society
Volume
330
Issue
2
Pages
L178–L197
Publication date
8 January 2026
Language
EN